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Abstract
Background Non-steroidal anti-inflammatory drugs (NSAIDs) are a major cause of upper gastro-intestinal (GI) ulceration 
and bleeding as well as cardiovascular (CV) diseases (e.g., myocardial infarction and stroke). A feature common to both 
these adverse events is a variety of vascular reactions. One approach to overcome these side effects has been the develop-
ment of nitric-oxide (NO)-donating NSAIDs. The NO is considered to overcome some of these vascular reactions caused by 
NSAIDs. Unfortunately, the NO-NSAIDs developed so far have not had the expected benefits compared with NSAIDs alone.
Objectives Using in vitro preparations it is hoped to gain insight into the vascular and smooth muscle reactions induced 
by NO-NSAIDs compared with NSAIDs as a basis for improving the protective responses attributed to the NO-donating 
properties of these drugs.
Methods A range of NO-NSAIDs was synthesized based on the esterification of NSAIDs with the nitro-butoxylate as a 
prototype of an NO-donor. These compounds, as well as NO-donor agents and NSAIDS, were examined for their possible 
effects on isolated segments of digital arteries of fallow deer, which provide a robust model for determining the effects of 
vasodilator and vasoconstrictor activities, in comparison with those of standard pharmacological agents.
Results The NO-NSAIDs were found to antagonise the smooth muscle contractions produced by 5-hydroxytryptamine 
(serotonin, 5-HT). However, while almost all their parent NSAIDs had little or no effect, with the exception of the R-(−)-
isomers of both ibuprofen and flurbiprofen, which caused vasodilatation, all the NO-NSAIDs tested antagonised the increase 
in tension produced by 5-HT.
Conclusions R-(−)-ibuprofen and R-(−)-flurbiprofen, along with the nitro-butoxyl esters of the NSAIDs examined, produce 
relaxation of segments of deer digital artery smooth muscle in vitro. The evidence presented suggests that their mechanism 
involves the release of NO or its products.
Keywords NSAIDs · Nitric oxide · Arterial · Deer · Smooth muscle · Gastrointestinal · Cardiovascular · NO-NSAIDs
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
amongst the most widely used drugs for prescription and 
non-prescription (‘over-the-counter’ or OTC) medications 
for the treatment of musculo-skeletal and various acute 
and chronic painful and inflammatory conditions (Rains-
ford 2007). Their use is associated with the development 
of serious adverse drug reactions (ADRs) especially in the 
gastro-intestinal (GI) tract of elderly patients with com-
promised health status (Rainsford et al. 2008; Lanas 2010; 
Lanas et al. 2010; Rahme and Bernatsky 2010) or those 
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with compromised cytochrome CYP2C9 metabolism (Car-
bonell et al. 2010); Süleyman et al. 2007). Over recent dec-
ades there has been increasing concern about the risks of 
NSAIDs, especially the cyclo-oxygenase (COX)-selective 
agents or coxibs, being associated with cardiovascular (CV) 
and cerebrovascular reactions including increased risk of 
myocardial infarction (Antman et al. 2007; McGettigan and 
Henry 2011; Olsen et al. 2012; Shau et al. 2012; Sudano 
et al. 2012; Caughey et al. 2011) and stroke (Barthélémy 
et al. 2011; Caughey et al. 2011; Varas-Lorenzo et al. 2011). 
These reactions are primarily related to hypertension that 
is exacerbated by NSAIDs (Barthélémy et al. 2011; Varas-
Lorenzo et al. 2011) as well as T-cell associated plaque-
instability in atherosclerosis (Padol and Hunt 2010; Rains-
ford 2010). The atherogenic promoting effects of NSAIDs 
may also be related to their propensity to divert arachidonic 
acid through the 5-lipoxygenase pathway (Yu et al. 2012).
Current concerns regarding the safe use of NSAIDs have 
centred on the combined GI and CV risks of these drugs 
(Lanas et  al. 2010; Scheiman and Hindley 2010; Salvo 
et al. 2011). A general feature that is common to both these 
adverse reactions is the effects of the NSAIDs on vascular 
reactions. Thus, in addition to the abovementioned vascu-
lar effects in CV disease, NSAIDs also cause microvascu-
lar injury in the early stages of the development of gastric 
mucosal damage (Rainsford 1983, 1992, 1993a, b; 1999; 
Gyömber et al. 1996a, b; Pasa et al. 2009; Tarnawski et al. 
2012). The NSAID-induced impairment of platelet aggrega-
tion contributes to the extravasation of blood from the dam-
aged microvasculature into the interstitial space, ischaemia 
and subsequent bleeding that accompanies the pathological 
injury to the gastric mucosa (Rainsford 1986, 1992; Gyöm-
ber et al. 1996a, b; Tarnawski et al. 2012). The initiation of 
vascular constriction by NSAIDs is considered to be related 
to excess production of vasoconstrictor peptido-leukot-
rienes which occurs from the diversion of arachidonic acid 
through the 5-lipoxygenase pathway as a result of NSAIDs 
inhibiting the cyclo-oxygenases (Rainsford 1986, 1993a, b, 
1999; Rainsford et al. 1995; Gyömber et al. 1996a, b). This 
is accompanied by accumulation, endothelial interactions 
and activation of polymorphonuclear (neutrophil) and other 
leucocytes that contribute to mucosal damage (Rainsford 
et al. 1995; 2012; McCafferty et al. 1995; Appleyard et al. 
1996; Wallace and Cirino 1994; Wallace 1997; Wallace 
et al. 1999; Muscará, et al. 2000). Aside from arachidonate 
metabolites (prostanoids, leukotrienes, lipoxins), nitric oxide 
(NO) is known to have a central role in the control of vas-
cular smooth muscle contraction, blood flow and platelet-
endothelial interactions (Brzozowski et al. 2008; Palileo and 
Kaunitz 2011; Tarnawski et al. 2012). However, it has also 
been shown that NO has actions that could be seen to be pro-
tective in the GI tract, by reducing vascular injury, enhanc-
ing production of protective mucus, reducing the effects of 
acid-pepsin and promotion of anti-thrombotic effects (Wal-
lace et al. 1993, 1994, 1999; Fiorucci and Distrutti 2011).
To this end, a range of NSAIDs coupled to an NO-
releasing moiety (NO-NSAIDs) has been developed, in the 
hope that such compounds, by releasing NO in the mucosa, 
would be less damaging to the GI tract. Some of these NO-
NSAIDs have been shown experimentally to cause less gas-
tric injury than the parent NSAIDs (Wallace et al. 1994, 
1999; Fiorucci and Distrutti 2011; Gund et al. 2014). The 
actions of these drugs in preventing GI injury are considered 
to result from the hydrolysis of an NO-ester link. Despite an 
immense amount of research, the outcomes from the long-
term studies with candidate NO-NSAIDs (e.g. NO-naproxen 
or naproxcinod) have been disappointing (Milton et al. 1999; 
Lowry 2010), although NO-aspirin may have potential as an 
anti-thrombotic agent (Wallace et al. 1999; Callingham et al. 
2012). In the present study, the actions of some NO-NSAIDs 
were compared with established NSAIDs and NO-donating 
analogues on the contractility of isolated segments common 
digital arteries of fallow deer (Dama dama; Callingham et al. 
2012).
Methods
Unless otherwise stated, NSAIDs, together with the interme-
diates used in the synthesis of the nitrobutoxy compounds 
described below, were obtained from Sigma-Aldrich (Poole, 
Dorset, UK). 5-Hydroxytryptamine (serotonin, 5-HT), phe-
nylephrine (PHE), the soluble guanylate cyclase (sGC) 
inhibitor 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one 
(ODQ) and other laboratory reagents were also obtained 
from Sigma-Aldrich (Poole, Dorset, UK).
The propionic acids, ibuprofen and flurbiprofen, are 
referred to as their racemic mixtures (rac). The R-(−)- and 
S-( +)-isomers of these drugs were gifts from Boots Health-
care International, Nottingham, UK.
Chemistry
The NO-NSAIDs (3a–i), were synthesized by a modification 
of the literature method (Wallace and Cirino 1994; Wallace 
et al. 1995) that is shown in Figs. 1 and 2.
General methods
Melting points are uncorrected and were determined on 
Stuart Scientific SMP3 apparatus. Infrared spectra were 
recorded with an ATI Mattson Genesis series FTIR spectro-
photometer. 1H NMR and 13C NMR spectra were recorded 
in  CDCl3 using a Brucker AC 250 spectrometer operating 
at 250 and 62.9 MHz, respectively. Chemical shifts (δ) are 
recorded in ppm downfield from  Me4Si as internal standard 
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and J values are given in Hz. Mass spectra were recorded 
with EI-VG 7070E mass spectrometer. Accurate masses 
were determined on VG Autospec EI mass spectrometer 
with magnetic sector instrument. Optical rotations were 
measured at 23 °C with a Bellingham and Stanley ADP 440 
polarimeter using dichloromethane as the solvent. All sol-
vents were dried and distilled by standard techniques.
Typical procedure for the preparation of the bromobutyl 
esters of NSAIDs [Wallace JL (1994; Wallace JL (1995)]: 
Ibuprofen sodium salt (1a) (11.40  g, 0.050  mol) and 
1,4-dibromobutane (43.20 g, 0.20 mol) in dry DMF (70 ml) 
were placed in a dry 250 ml round-bottomed flask that was 
equipped with a reflux condenser and a  CaCl2 drying tube. 
The mixture was magnetically stirred and heated in an 
oil bath at 80–90 °C overnight after which the DMF was 
removed by distillation under reduced pressure. The residue 
was extracted with diethyl ether (250 ml) and washed with 
hydrochloric acid (2 M, 100 ml), saturated sodium hydro-
gen carbonate solution (50 ml) and water (100 ml), respec-
tively. The organic layer after drying  (MgSO4) was filtered 
and evaporated to yield an oily residue (23.30 g) which was 
shown to be impure by TLC (1:3, ethyl acetate: petroleum 
ether). Purification by flash column chromatography gave 
the bromobutyl ester of (R/S)-ibuprofen (2a) (Rf 0.79) 
(7.64 g, 45%) as a colourless oil; IR ν (tlf) 1736   cm−1 
(> C=O); 1H NMR δ  (CDCl3) 0.92 (6H, d, J = 7.5 Hz, 2Me), 
1.50 (3H, d, J = 8 Hz, Me), 1.65—1.90 (5H, m, −  CH2CH2- 
and > CH-), 2.48 (2H, d, J = 8 Hz, −  CH2–Ar), 3.33 (2H, 
t, J = 7.5 Hz, −  CH2Br), 3.70 (1H, q, J = 8 Hz, ArCH <), 
4.15 (2H, t, J = 7.5 Hz, − O–CH2-), 7.10 (2H, d, AB system 
J = 8.5 Hz, Ar), 7.22 (2H, d, AB system J = 8.5 Hz, Ar); 13C 
NMR δ  (CDCl3) 18.21, 22.24, 24.94, 27.05, 29.00, 30.04, 
32.88, 44.95, 63.65, 127.35, 129.17, 137.61, 140.39, 174.53; 
MS m/z 340/342  (M+,  Br79/Br81). HRMS: m/z = 340.1052 
 (M+).  C17H25O2Br79 required 340.1039  (M+). The bro-
mobutyl ester (2b) was made from (R)-(-)-ibuprofen (1b) 
(200 mg, 0.97 mmol), 60% sodium hydride dispersion in 
mineral oil (23.3 mg,0.97 mmol) and 1,4-dibromobutane 
(1.0 g, 4.6 mmol) in dry DMF (5 ml) as a colourless oil 
(250 mg, 75.5%), (Rf 0.64, 1:8, ethyl acetate: petroleum 
ether). HRMS: m/z = 340.1055  (M+).  C17H25O2Br79 required 
340.1039  (M+). The bromobutyl ester (2c) was made from 
(S)-( +)-ibuprofen (1c) (1.79 g, 8.69 mmol), 60% sodium 
hydride dispersion in mineral oil (350 mg,8.69 mmol) and 























(2a) (R/S)-ibuprofen (45% yield)
(2b) (R)(-)-ibuprofen (75.5% yield)
(2c) (S)(+)-ibuprofen (34% yield)
(2d) naproxen (33.5% yield)
(2e) aspirin (89% yield)
(2f) indomethacin (57% yield)
(2g) (R)(-)-flurbiprofen (58% yield)
(2h) (S)(+)-flurbiprofen (67% yield)
(2i) (R/S)-flurbiprofen (55% yield)
(3a) (R/S)-ibuprofen (74% yield)
(3b) (R)(-)-ibuprofen (46% yield)
(3c) (S)(+)-ibuprofen (90% yield)
(3d) naproxen (64% yield)
(3e) aspirin (56% yield)
(3f) indomethacin (89% yield)
(3g) (R)(-)-flurbiprofen (84% yield)
(3h) (S)(+)-flurbiprofen (84% yield)

























Fig. 1  General scheme for the synthesis of NO-NSAIDs (3a–i) in two steps by  SN2 reactions
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Fig. 2  Summary of the synthe-
sis of NO-NSAIDs by a method 
modified from that of Wallace 
et al (1994, 1995). a: R/S-
ibuprofen, b: R-(-)-ibuprofen, c: 
S-(+)-ibuprofen, d: S-(+)-nap-
roxen, e: aspirin (Schemes 1-3), 
f: indomethacin (Scheme 4), g: 
R-(-)-flurbiprofen), S-(+)-flur-
biprofen and R/S-flurbiprofen 
(Scheme 5)















a = (R/S)-racemate (74% yield)
b = (R)-(-)-isomer (46% yield)
c = (S)-(+)-isomer (90% yield)
a = (R/S)-racemate (45% yield)
b = (R)-(-)-isomer (75.5% yield)





Scheme 2. Synthesis of nitroxybutyl ester of naproxen













nitroxybutyl ester (64% yield)

























bromobutyl ester (89% yield)
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a colourless oil (1.20 g, 34%). HRMS: m/z = 340.1050  (M+). 
 C17H25O2Br79 required 340.1039  (M+).
The bromobutyl ester (2d) was made from naproxen 
(1d) (8.50 g, 36.9 mmol), potassium carbonate (5.50 g, 
20 mmol) and 1,4-dibromobutane (32 g, 80 mmol) in dry 
DMF (55 ml) at 120°C overnight as a colourless oil (4.50 g, 
33.5%) (Rf 0.57; 1:3, ethyl acetate: petroleum ether); 1H 
NMR δ  (CDCl3) 1.50–1.65 (5H, m,-CH2 and Me), 1.80 (2H, 
m, −  CH2), 3.32 (2H, t, J = 7.5 Hz, −  CH2Br), 3.80–3.95 
(4H, m, > CH and OMe), 4.13 (2H, t, J = 7.5 Hz,  OCH2-), 
7.10–7.20 (2H, m, H-5 and H-7), 7.45 (1H, d, J = 9 Hz, 
H-3), 7.65–7.75 (3H, m, H-1, H-4 and H-8); 13C NMR δ 
 (CDCl3) 18.29, 27.07, 29.30, 32.92, 45.35, 55.16, 63.60, 
105.49, 118.89, 125.80, 126.06, 127.05, 128.80, 129.14, 
133.59, 135.52, 157.54, 174.47; MS m/z 364/366  (M+,  Br79/
Br81). HRMS: m/z = 364.0690  (M+).  C18H21O3Br79 requires 
364.0675  (M+).
The bromobutyl ester (2e) was made from aspirin (1e) 
(18.00 g, 0.10 mol), sodium hydride (60% dispersion in 
mineral oil, 4.00  g, 0.16  mol) and 1,4-dibromobutane 
(90.0 g, 0.41 mol) in dry DMF (100 ml) at 80 °C overnight 
as a colourless oil (23.0 g, 89%)  (Rf 0.62;1:4, ethyl acetate: 


























nitroxybutyl ester (89% yield)


















g = (R)-(-) enantiomer
h = (S)-(+) enantiomer
i = (R/S)- racemate
g = (R)-(-) enantiomer (58% yield)
h = (S)-(+) enantiomer (67% yield)
i = (R/S)- racemate (55% yield)
g = (R)-(-) enantiomer (84.5% yield)
h = (S)-(+) enantiomer (84% yield)
i = (R/S)- racemate (80% yield)
Fig. 2  (continued)
 B. A. Callingham et al.
1 3
petroleum ether); 1H NMR δ  (CDCl3) 1.70–1.80 (4H, m, 
−  CH2CH2-), 2.30 (3H, s, Me), 3.35 (2H, t, J = 7.5 Hz, 
 CH2Br), 4.40 (2H, t, J = 7.5  Hz,  OCH2-), 7.10 (1H, d, 
J = 8.3 Hz, H-3), 7.30 (1H, t, J = 8.3 Hz, H-4), 7.55 (1H, t, 
J = 8.3 Hz, H-5), 7.97 (1H, d, J = 8.3 Hz, H-6); 13C NMR δ 
 (CDCl3) 20.70, 27.15, 29.09, 32.87, 64.08, 123.09, 123.69, 
125.87, 129.66, 131.48, 133.76, 150.55, 164.24, 169.95; MS 
m/z 314/316  (M+,  Br79/Br81). HRMS: m/z = 314.0168  (M+).
C13H15O4Br79 requires 314.0154  (M+).
The bromoester (2f) was prepared from indometha-
cin (1f) (17.86 g, 0.05 mol), potassium carbonate (7.0 g, 
0.05 mol) and 1,4-dibromobutane (45.0 g, 0.20 mol) in dry 
DMF (70 ml) at 120 °C overnight as a cream coloured solid, 
m.p. 69.8–70.5 °C, (14.0 g, 57%), (Rf 0.50; 1:4, ethyl ace-
tate: petroleum ether); 1H NMR δ  (CDCl3) 1.70–1.90 (4H, 
m, −  CH2CH2-), 2.40 (3H, s, Me), 3.36 (2H, t, J = 7.5 Hz, 
−  CH2Br), 3.66 (2H, s, −  CH2), 3.83 (3H, s, OMe), 4.15 
(2H, t, J = 7.5 Hz,  OCH2-), 6.65 (1H, d, J = 8.5 Hz, H–H-
6), 6.87 (1H, d, J = 8.5 Hz, H-7), 6.97 (1H, s, H-4), 7.47 
(2H, d, J = 8.5 Hz, ortho to Cl), 7.68 (2H, d, J = 8.5 Hz, 
ortho to N–CO); 13C NMR δ  (CDCl3) 13.22, 27.14, 29.12, 
30.24, 32.78, 55.59, 63.89, 101.18, 111.48, 112.39, 114.84, 
128.98, 130.45, 130.67, 131.04, 133.75, 135.78, 139.11, 
155.91, 168.13, 170.66; MS m/z 491.5/493.5  (M+,  Br79/
Br81). HRMS: m/z = 412.1332  (M+).  C23H23NO4Cl35Br79 
requires 412.1316  (M+).
The bromoester (2 g) was prepared from (R)-(-)-2-(3-
fluorobiphenyl-4yl)propanoic acid (1g) (1.00 g, 4.09 mmol), 
60% sodium hydride dispersion in mineral oil (160 mg, 
4.09 mmol) and 1,4-dibromobutane (3.0 g, 13.9 mmol) in 
dry DMF (20 ml) at 95–100 °C overnight as a colourless 
oil (1.44 g) which was purified by flash column chroma-
tography (1:9, ethyl acetate: petroleum ether) to give pure 
(2 g) (0.90 g, 58%),  (Rf 0.60; 1:9, ethyl acetate: petro-
leum ether); IR ν (tlf) 1733   cm−1 (> C=O); 1H NMR δ 
 (CDCl3) 1.53 (3H, d, J = 7.24 Hz, Me), 1.70–1.91 (4H, 
m, −  CH2–CH2-), 3.36 (2H, t, J = 6.46 Hz, Br–CH2), 3.75 
(1H, q, J = 7.24  Hz, > CH–CO-), 4.13 (2H, t, J = 6.20, 
O–CH2), 7.10–7.17 (2H, m, Ar), 7.35–7.56 (6H, m, Ar); 13C 
NMR δ  (CDCl3) 18.58, 27.57, 29.57, 32.63, 45.37, 64.36, 
115.58, 123.70, 127.86, 128.41, 128.87,129.74, 130.92, 
131.10, 135.80, 142.20, 158.07, 162.00, 174.16. HRMS: 
m/z = 378.0647  (M+).  C19H20O2FBr79 required 378.0632 
 (M+).
The bromoester (2  h) was prepared from (S)-(+)-
2-(3-fluorobiphenyl-4yl)propanoic acid  (1h) (0.50  g, 
2.05 mmol), 60% sodium hydride dispersion in mineral 
oil (80 mg, 2.05 mmol) and 1,4-dibromobutane (1.5 g, 
6.95 mmol) in dry DMF (12 ml) at 95–100 °C overnight 
as a colourless oil (0.80 g) which was purified by flash col-
umn chromatography (1:9, ethyl acetate: petroleum ether) 
to give pure 2 h (0.52 g, 67%), HRMS: m/z = 378.0650 
 (M+).  C19H20O2FBr79 required 378.0632  (M+).
The bromoester (2i) was prepared from (R/S)-2-(3-
fluorobiphenyl-4yl)propanoic acid (1i) (4.88 g, 20 mmol), 
60% sodium hydride dispersion in mineral oil (800 mg, 
20 mmol) and 1,4-dibromobutane (15 g, 69.5 mmol) in 
dry DMF (100 ml) at 95–100 °C overnight as a colour-
less oil (4.20 g, 55%) which was purified from residues of 
1,4-dibromobutane by evaporation under high vacuum at 
100 °C and was pure according to TLC (1:9, ethyl acetate: 
petroleum ether).
Typical procedure (Wallace and Cirino 1994; Wallace 
et al. 1995) for preparing the nitroxybutyl esters of the 
NSAIDs is illustrated by the synthesis of nitroxybutyl ester 
of ibuprofen (3a): A mixture of ibuprofen bromobutyl ester 
(2a) (8.00 g, 0.02 mol) and silver nitrate (8.00 g, 0.04 mol) 
in dry distilled acetonitrile (56 ml) was stirred in an oil 
bath at 50 °C in a dry round bottomed flask equipped with 
a  CaCl2 drying tube until TLC (1:4, ethyl acetate: petro-
leum ether) showed the reaction to be complete (5 h). The 
mixture was decanted into deionised water and extracted 
with DCM (150 ml). The organic layer after drying  (MgSO4) 
was filtered and evaporated to yield an oily residue which 
was purified by flash chromatography (1:4; ethyl acetate: 
petroleum ether) to give nitroxybutyl ester of ibuprofen (3a) 
 (Rf 0.68) (4.78 g, 74%) as a colourless oil, IR ν (tlf) 1733 
(> C=O), 1630  cm−1  (ONO2); 1H NMR δ  (CDCl3) 0.92 (6H, 
d, J = 7.5 Hz, 2Me), 1.50 (3H, d, J = 8 Hz, Me), 1.60–1.74 
(4H, m, −  CH2CH2-), 1.78–1.95 (1H, m, > CH-), 2.45 (2H, 
d, J = 8 Hz, −  CH2-Ar), 3.70 (1H, q, J = 8 Hz, ArCH <), 
4.05–4.18 (2H, m, − O–CH2-), 4.37 (2H, t, J = 7.5 Hz, 
−  CH2ONO2), 7.1 (2H, d, AB system J = 7 Hz, Ar), 7.22 
(2H, d, AB system J = 7 Hz, Ar); 13C-NMR δ  (CDCl3) 
18.16, 22.19, 24.03, 25.00, 30.02, 44.91, 63.44, 127.21, 
129.17, 137.55, 140.48, 174.47; MS m/z 323  (M+). HRMS: 
m/z = 323.1740  (M+).  C17H25NO5 requires 323.1734  (M+).
Nitroxybutyl ester (3b) was obtained from the bromoe-
ster (2b) (250 mg, 0.73 mmol) and silver nitrate (620 mg, 
3.65 mmol) in acetonitrile (5 ml) after purification (1:8; 
ethyl acetate: petroleum ether) as a colourless oil (108 mg, 
46%), (Rf 0.45). HRMS: m/z = 323.1743  (M+).  C17H25NO5 
requires 323.1734  (M+).
Nitroxybutyl ester (3c) was obtained from the bromoester 
(2c) (1.17 g, 3.43 mmol) and silver nitrate (3 g, 17.6 mmol) 
in acetonitrile (40 ml) after purification (1:8; ethyl acetate: 
petroleum ether) as a colourless oil (1.00 g, 90%).
Nitroxybutyl ester (3d) was obtained from the bromoester 
(2d) (4.47 g, 12 mmol) and silver nitrate (4.08 g, 24 mmol) 
in acetonitrile (40 ml) as a colourless oil (2.67 g, 64%)  (Rf 
0.55); IR ν (tlf) 1729 (> C=O), 1627  cm−1  (ONO2); 1H-
NMR δ  (CDCl3) 1.58 (3H, d, J = 7.2 Hz, Me), 1.65–1.68 
(4H, m, −  CH2CH2-), 3.85 (1H, q, J = 7.2 Hz, > CH), 3.92 
(3H, s, OMe), 4.12 (2H, t, J = 6.3 Hz,  OCH2-), 4.31 (2H, 
t, J = 6.3 Hz, −  CH2ONO2), 7.12–7.17 (2H, m, H-7 and 
H-5), 7.41 (1H, d, J = 8.2 Hz, H-3), 7.66–7.73 (3H, m, H-1, 
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H-4 and H-8); 13C-NMR δ  (CDCl3) 18.18, 23.27, 24.73, 
45.31, 55.15, 63.59, 72.19, 105.47, 118.92, 125.78, 125.97, 
127.06, 128.77, 129.08, 133.59, 135.44, 157.56, 174.43; MS 
m/z 347  (M+). HRMS: m/z = 347.1375  (M+).  C18H21NO6 
requires 347.1370  (M+).
Nitroxybutyl ester (3e) was obtained from the bro-
moester (2e) (23.0 g, 73 mmol) and silver nitrate (24.0 g, 
0.14 mol) in dry acetonitrile (180 ml) as a colourless oil 
(12.17 g, 56%)  (Rf 0.45), IR ν (tlf) 1766, 1724 (> C=O), 
1627  cm−1  (ONO2); 1H-NMR δ  (CDCl3) 1.82–1.87 (4H, 
m, −  CH2CH2-), 2.33 (3H, s, Me), 4.29 (2H, t, J = 6.3 Hz, 
 OCH2-), 4.48 (2H, t, J = 6.3 Hz, −  CH2ONO2), 7.09 (1H, 
dd, J 8.3 and 1.0 Hz, H-3), 7.30 (1H, td, J = 8.3 and 1.0 Hz, 
H-4), 7.55 (1H, td, J = 8.3 and 1.0 Hz, H-5), 7.98 (1H, dd, 
J = 8.3 and 1.0 Hz, H-6); 13C-NMR δ  (CDCl3) 20.79, 23.41, 
24.85, 30.65, 63.94, 72.47, 123.03, 123.69, 126.06, 131.36, 
133.81, 150.55, 164.14, 169.42; MS m/z 297  (M+). HRMS: 
m/z = 297.0856  (M+).  C13H15NO7 required 297.0849  (M+).
Nitroxybutyl ester (3f) was obtained from the bro-
moester (2f) (6.0 g, 12 mmol) and silver nitrate (4.84 g, 
66 mmol) in dry acetonitrile (30 ml) as a light-brown paste 
(5.1 g, 89%)  (Rf 0.55), IR ν (tlf) 1734, 1683 (> C=O), 
1628  cm−1  (ONO2); 1H-NMR δ  (CDCl3) 1.71–1.78 (4H, 
m, −  CH2CH2-), 2.40 (3H, s, Me), 3.68 (2H, s –  CH2CO), 
3.84 (3H, s, OMe), 4.12–4.17 (2H, m,  OCH2-), 4.37–4.42 
(2H, m, −  CH2ONO2), 6.67 (1H, dd, J = 9.3 and 2.6 Hz, 
H-6), 6.86 (1H, d, J = 9.3 Hz, H-7), 6.95 (1H, d, J = 2.6 Hz, 
H-4), 7.49 (2H, d of AB system, J = 8.7 Hz, ortho to Cl), 
7.65 (2H, d of AB system, J = 8.7 Hz, ortho to > NCO); 13C-
NMR δ  (CDCl3) 13.16, 23.38, 24.80, 30.17, 55.54, 63.87, 
72.37, 101.27, 111.34, 112.31, 114.83, 128.98, 130.43, 
130.67, 131.02, 133.74, 135.81, 139.10, 155.90, 168.11, 
170.61; MS m/z 474.5  (M+). HRMS: m/z = 474.1272  (M+). 
 C23H23N2O7Cl35 required 474.11945  (M+).
(R)-(-)-Nitroxybutyl ester (3 g) was obtained from the 
(R)-(-)-bromoester (2 g) (870 mg, 2.30 mmol) and silver 
nitrate (3.12 g, 18.3 mmol) in dry acetonitrile (20 ml) as a 
colourless oil (700 mg, 84.5%),  (Rf 0.55; 1:9, ethyl acetate: 
petroleum ether); [α] = − 14.87°; IR ν (tlf) 1734 (> C=O), 
1627   cm−1  (ONO2); 1H-NMR δ  (CDCl3) 1.51(3H, d, 
J = 7.24 Hz, Me), 1.63–1.73(4H, m, −  CH2CH2-), 3.73(1H, 
q, J = 7.24 Hz, > CH-CO), 4.10(2H, t, J = 5.69 Hz, −  OCH2-), 
4.37(2H, t, J = 5.95, −  CH2–ONO2), 7.07–7.17(2H, m, Ar), 
7.28–7.45(4H, m, Ar), 7.48–7.55(2H, m, Ar); 13C-NMR δ 
 (CDCl3) 18.53, 23.69, 25.20, 45.31, 64.31, 72.94, 115.53, 
123.97, 127.77, 128.28, 128.55, 128.85, 129.03, 129.52, 
131.11, 135.77, 142.13, 158.07, 162.00, 174.16; HRMS: 
m/z = 361.1364  (M+).  C19H20NO5F required 361.1326  (M+).
(S)-( +)-Nitroxybutyl ester (3 h) was obtained from the 
(S)-( +)-bromoester (2 h) (500 mg, 1.30 mmol) and sil-
ver nitrate (1.76 g, 10.3 mmol) in dry acetonitrile (15 ml) 
after purification as a colourless oil (400  mg, 84%); 
[α] =  + 13.41°. HRMS: m/z = 361.1429(M+).  C19H20NO5F 
required 361.1326  (M+).
(R/S)-Nitroxybutyl ester (3i) was obtained from the 
(R/S)-bromoester (2i) (4.20 g, 11 mmol) and silver nitrate 
(9.40 g, 55.3 mmol) in dry acetonitrile (100 ml) after purifi-
cation as a colourless oil (3.20 g, 80%) [Wallace and Cirino 
1994; Wallace et al. 1995; Menzel and Kolarz 1997).
Pharmacology
Deer common digital artery contractility studies
The methods employed were those previously described 
(Callingham et al. 2012). The experiments were performed 
on isolated segments of the left common digital artery of the 
fallow deer (Dama dama) slaughtered at the Denham Park 
Estate in Bury St. Edmunds (UK) for venison according to 
E.U. Red Meat regulations. The arteries, from deer of either 
sex, were removed and transported over ice in vials contain-
ing physiological saline solution (PSS; composed of: NaCl 
118 mM, KCl 4.57 mM,  CaCl2 2.5 mM,  NaHCO3 25 mM, 
 MgSO4 1.19 mM,  KH2PO4 1.19 mM, glucose 5.55 mM at 
pH 7.4, aerated with 95%  O2 and 5%  CO2) (Callingham et al. 
2012). On arrival at the laboratory, the vessels were dis-
sected free of extraneous tissues and stored, until required, 
in fresh aerated PSS at 4 °C. With changes of PSS daily, the 
vessels remained viable for up to 10 days.
Segments (approximately 3 mm in length), were mounted, 
in 10 ml, water-jacketed organ baths at 37 °C and attached 
to Harvard isometric transducers (0–50 g sensitivity), con-
nected, via Harvard amplifiers and A/D converters (Pow-
erLab® 8/35, ADInstruments Ltd, Bishops Mews, Trans-
port Way, Oxford, OX4 6HD, UK) for computer recording 
of developed tension. Resting tension was adjusted to 3 g, 
which was maintained during a 45 min period of acclimati-
sation and beyond. The integrity of the vascular endothelium 
was tested by measuring the relaxation produced by addition 
of  10–6 M histamine to segments pre-contracted with either 
 10–6 M 5-HT or  10–6 M PHE; since acetylcholine, the agent 
normally employed to detect functional endothelium is with-
out effect in this preparation. In each experiment, the vessel 
rings were contracted, either with single concentrations or 
graded concentrations of (5-HT).
Cumulative changes in tension to applied agents were 
plotted as percentages of maximum responses against log 
concentrations of the relevant agent and fitted to the Hill 
equation by use of the non-linear regression facility in 
Kaleidagraph® (Synergy Software, 2457 Perkiomen Ave., 
Reading PA, USA 19,606) with n-values referring to the 
number of animals used. Tests for statistical significance 
were performed using the unpaired t-test.
In Figs. 3, 4, 5, 6, 7 inclusive, parameters for 5-HT 
 (EC50 ± s.e.m. and maximum tension ± s.e.m.) were 
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obtained from the mean regressions. In Figs. 8, 9, 10, 11 
inclusive, while the regressions were derived as above, 
tests for statistical significance were applied to individual 
mean data points and identified by asterisks as appropriate.
Drugs and reagents
Stock solutions of the NSAIDs were made by first dissolv-
ing a few milligrams of the compound in 0.25 ml of DMSO 
(dimethyl sulphoxide) and made up to  10–2 M with an appro-
priate volume of deionised water. These solutions, together 
with any dilutions, were kept on ice until used.
This investigation tested four NSAIDs (aspirin, ibupro-
fen, naproxen, and indomethacin) and four corresponding 
NO-donating NSAIDs (aspirin nitroxybutyl ester, ibupro-
fen nitroxybutyl ester, naproxen nitroxybutyl ester and indo-
methacin nitroxybutyl ester).
Stock solutions of  10−2 M 5-HT), phenylephrine (PHE) 
and histamine were prepared and kept at 4 °C and diluted 
with deionised water for use on the day of the experiment 
and kept on ice. Solutions of methylene blue for use as an 
inhibitor of nitric oxide synthase (Mayer et al. 1993) were 
made up on the day they were required.
Experimental protocol
Rings of 2–3 mm length were cut from the digital arteries 
using scissors and mounted in the organ bath by sliding 
the two hooks into the lumen of the artery. Each water 
bath was filled with PSS (buffered salt solution) and con-
tinuously aerated with 95%  O2 5%  CO2. The jackets sur-
rounding the water baths had water heated to 37 °C con-
tinuously pumped through them to maintain physiological 
temperature in the water baths. The day’s stock solution 
flask of aerated PSS was also kept submerged in the water 
bath so that it was at the correct temperature when it was 
added to the organ baths. The tension pulled by the rings 
was adjusted to 3 g before each experiment was begun.
On the morning of each day of experiments, the artery 
segments were pre-contracted with  10−5 M 5-HT as this 
concentration was sufficient to achieve the maximum con-
tractile response; previous studies had shown to induce 
the rings to respond well to subsequent drug additions. 
When the vessels had reached maximum contraction, 
 10−6 M histamine was added to the organ baths to test for 
the presence of a functional endothelium. The organ baths 
were then washed out and filled with fresh PSS. The rings 
were left to relax for an hour, with the tension returned 
to 3 g at intervals and the experiment proper was begun.
Data recording
The transducers were calibrated by use of the PowerLab® 
calibration facility and tested for linearity of response by 
attaching weights from 1 to 20 g. All data were processed 
by use of LabChart® (ADInstruments) on the recording 
computer.
The cumulative changes in tension to applied agents were 
plotted as percentages of maximum responses against log con-
centrations of the relevant agent and fitted to the Hill equation by 
non-linear regression, with n-values referring to the number of 
animals used. Only rings from left feet were used after ensuring, 
having previously that there were no differences in responses 
between rings taken from either foot, to ensure that the n-values 
truly represented individual animals. Tests for statistical signifi-
cance were performed using the unpaired t-test.
Results
Nitroxybutyl-aspirin (NO-aspirin) effectively reduced the 
contractile responses of digital artery segments produced 
by increasing concentrations of 5-HT, whereas aspirin was 
without effect (Fig. 3); as was aspirin butyl ester (data not 
shown). When used at a concentration of  10–4 M, NO-aspi-
rin increased the  EC50 of 5-HT to 9.1 ×  10–7 ± 0.7 ×  10–8 M 
(n = 3) from 5.2 ×  10–7 ± 0.7 ×  10–8  M. (n = 3). How-
ever, when this experiment was repeated to ascertain 
if  10–4  M methylene blue would reduce the effective-
ness of NO-aspirin by sequestering the released NO, 
there was no significant change in  EC50 values, which 
were control; 8.8 ×  10–8 ± 0.7 ×  10–8  M, methylene blue 
alone; 4.4 ×  10–7 ± 0.3 ×  10–8 M (n = 3), NO-aspirin alone; 
5.99 ×  10–6 ± 0.52 ×  10–6 M (n = 3) and NO-aspirin plus 
methylene blue; 5.25 ×  10–6 ± 1.36 ×  10–6 M (n = 3), (Fig. 4).
When the maximum tension that could be developed by 
the segments, in response to applied 5-HT, was examined, 
the relaxation in tension produced by NO-aspirin alone was 
reduced from 50 to 30% in the presence of methylene blue 
(Fig. 4). Of the other NSAIDs and their nitroxy-derivatives, 
examined, indomethacin and naproxen, produced similar 
results (Figs. 5, 6, 7).
However, when the effects produced by racemic (rac)-
ibuprofen and nitroxybutyl-ibuprofen (NO-ibuprofen) were 
compared, on 5-HT pre-contracted arterial segments, both 
were effective at reducing the responses to electrical stim-
ulation, with no significant difference (p > 0.05) in effect 
between them (Fig. 7). Another phenyl-propioinic acid, rac-
flurbiprofen and its nitroxybutyl derivative (NO-flurbipro-
fen) produced similar results (data not shown). It was also 
found that rac-ibuprofen produced a reversible relaxation of 
vessel segments, when they had been pre-contracted with 
3 ×  10–6 M phenylephrine (PHE), to a maximum tension of 
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16.5 ± 15% of control, with an EC50 of 2.97 ×  10–4 ±  10–5 M 
(n = 7: p < 0.01). In view of this unexpected relaxation pro-
duced by ibuprofen and flurbiprofen, further experiments 
were done to attempt to discover their mode of action.
Furthermore, since ibuprofen and flurbiprofen are diaste-
reo-isomeric (racemic)-mixtures, it was decided to examine 
the relaxant effects of their individual enantiomers on 5-HT 
pre-contacted arterial segments. In both cases, the R-(−)-
enantiomers were significantly (p < 0.01) more potent than 
the corresponding S-( +)-isomers (Figs. 8, 9).
Removal of the vascular endothelium (a source of NO) 
reduced (p < 0.001) but did not eliminate the vasodilator 
actions of R-(−)- ibuprofen (Fig. 10.), suggesting a role for 
NO in the relaxation produced.
These relaxant effects were reduced to near control values 
by the soluble guanylate cyclase (sGC) inhibitor, 1H-[1,2,4]-
oxadiazolo[4,3-a]quinoxalin-1-one (Feelisch et al. 1999; 
ODQ: 1 ×  10–5 M) (Fig. 11).
Discussion
These results demonstrate that the NO-donating analogues 
of aspirin, indomethacin, etc., significantly reduced the 
contractile responses of vascular smooth muscle to electri-
cal stimulation and to applied 5-HT and PHE (results not 
shown), while, with the exception of ibuprofen and flurbi-
profen, the parent NSAIDs were without effect. It was also 
shown that methylene blue (an inhibitor of NO action) sig-
nificantly reduced the effect of NO-aspirin (Fig. 4), as well 
as other NO-NSAIDs (data not shown). In addition, the pres-
ence of haemoglobin had the same effect on NO-aspirin. 
This suggests that, in the presence of blood, in particular, the 
actions of NO-NSAIDs could be limited (data not shown).
The fact that R-(−)-ibuprofen produced a relaxation of a 
similar magnitude to racemic NO-ibuprofen suggests that 
either R-(−)-ibuprofen released NO on a similar scale to 
NO-ibuprofen, or that it caused relaxation by some other 
means. There are several other means possible, including the 
induction of iNOS or direct activation of soluble guanylate 
cyclase. Some previous work has been done on the possible 
involvement of ibuprofen with iNOS. One study suggests 
that the concentration of NO in cells can be raised by the 
presence of ibuprofen, through the induction of iNOS (Men-
zel and Kolarz 1997). This showed that, at therapeutically 
attainable concentrations (1–30 μM), iNOS was induced 
similarly by both stereoisomers of ibuprofen, although only 
slightly more by the R-(-)-enantiomer. In another study, ibu-
profen significantly increased the spontaneous production of 
NO, which was unaffected by an iNOS inhibitor, suggesting 
instead that eNOS was involved (Miyamoto et al. 2007). This 
is relevant to the present study due to the observations that 
while S-( +)-ibuprofen was shown to have relatively little 
effect, this was not significantly different from the vehicle 
control and R-(−)-ibuprofen caused appreciable relaxation. 
However, contrary to this, there is evidence to suggest that 
ibuprofen, in fact, reduces NO produced in stressful situa-
tions, for example in the presence of bacterial endotoxin, 
where increased NO production leads to a fall in mean arte-
rial blood pressure. Ibuprofen blunts this effect, and the data 
suggests that ibuprofen down-regulates NO production in 
human subjects (Vandivier et al. 1999).
The reduction in the relaxation caused by rac-ibupro-
fen was blocked by ODQ (Feelisch et al. 1999) (Fig. 11), 
strongly suggests that the relaxation is mediated through 
cGMP. Removing the endothelium of the vessels, which 
Fig. 3  Effect of aspirin and NO-aspirin on the cumulative 
log[concentration]—vasoconstrictor responses of fallow deer 
isolated arterial rings to 5-HT. A comparison of the contractile 
responses of arterial rings to 5-HT in the presence and absence 
of aspirin  (10–4  M) and NO-aspirin  (10–4  M), showed that aspi-
rin had no significant effect on the responses of the arterial rings 
to 5-HT (P > 0.05), while NO-aspirin, significantly reduced the 
maximum tension produced (P < 0.001) together with a signifi-
cant increase in the  EC50 of applied 5-HT (P < 0.001), when com-
pared with responses of control rings and rings in the presence 
of aspirin. Control: n = 19,  EC50 = 4.29 ×  10–7 ± 1.63 ×  10–8  M, 
max. developed tension (percent) = 100.9 ± 0.81. Vehi-
cle: n = 8,  EC50 = 3.53 ×  10–7 ± 2.61 ×  10–8  M, max. devel-
oped tension (percent) = 91.24 ± 1.12. Aspirin: n = 8, 
 EC50 = 4.74 ×  10–7 ± 1.88 ×  10–8  M, max. developed ten-
sion (percent) = 93.43 ± 1.40. NO-Aspirin: n = 12, 
 EC50 = 2.05 ×  10–6 ± 1.02 ×  10–7  M, max. developed tension (per-
cent) = 59.19 ± 0.83. There was no significant difference between 
the responses of control vessels and those to which vehicle had been 
added volumes appropriate to the concentrations of applied drugs 
(P > 0.05)
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should prevent any action of NOS, had no significant effect 
on the relaxation. Attempts to employ L-nitro arginine 
(L-NAME) to block endogenous NO production have been 
complicated by its action (after potentiating contraction as 
expected due to the reduction in local NO) to cause a reduc-
tion in tension on its own.
By comparison, another diastereoisomeric propionic acid, 
rac-flurbiprofen had similar properties to the ibuprofen iso-
mers, with the R-(–) enantiomer causing significantly greater 
relaxation than the S-( +)- enantiomer; the magnitude of the 
relaxation produced being less than with the same concen-
trations of ibuprofen enantiomers. The other difference is 
that the NO-flurbiprofen compounds appear to have a more 
potent vasorelaxant effect than the parent compound. This 
might be due to an increased ability to release NO. There 
is little difference between the magnitude of reduction in 
response by the two enantiomers of the NO-flurbiprofen, 
suggesting that they can release NO while not directly acti-
vating sGC. If activating sGC were important in their action, 
it would be expected that the R-enantiomer would have a 
greater effect than the S-enantiomer. As this is not the case, 
it seems likely that they are producing relaxation via NO.
The results overall suggest that R-(–)-ibuprofen directly 
activates sGC. They also suggest that NO-ibuprofen does 
not work in the same fashion. If it did then it would be 
likely to produce greater relaxation given its coupling with 
a nitric oxide-releasing moiety. The combination of the 
release of NO and direct activation of sGC by ibuprofen 
should produce a greater relaxation than just the activation 
of sGC alone but it does not, suggesting that the change in 
the chemical composition by esterification causes sufficient 
change in structure to prevent the compound working in the 
Fig. 4  Effect of methylene blue on the cumulative 
log[concentration]—vasoconstrictor responses of fallow deer 
isolated arterial rings to 5-HT. In the presence of  10–4  M meth-
ylene blue, a direct nitric oxide synthase and guanylyl cyclase 
inhibitor (Mayer et  al. 1993), the contractile responses of the arte-
rial rings to 5-HT were enhanced, with a significant decrease 
(P < 0.001) of the  EC50 value, without effect on the maximum 
tension developed. In the absence of methylene blue, NO-aspi-
rin produced a significant reduction in the maximum response 
to 5-HT (P < 0.01) and a significant increase in  EC50 value of 
5-HT (P < 0.001). The presence of methylene blue, had no sig-
nificant effect on the NO-aspirin induced increased  EC50 value 
but appeared to reduce its reduction of the maximum effect 
of 5-HT. Control: n = 3,  EC50 = 8.83 ×  10–7 ± 6.83 ×  10–8  M, 
max. developed tension (percent) = 99.26 ± 2.43. Meth 
Blue: n = 3,  EC50 = 4.44 ×  10–7 ± 3.16 ×  10–8  M, max. devel-
oped tension (percent) = 99.19 ± 1.90. NO-Aspirin: n = 3, 
 EC50 = 5.99 ×  10–6 ± 5.15 ×  10–7  M, max. developed ten-
sion (percent) = 57.69 ± 3.03. Meth Blue & NO-aspirin: n = 3, 
 EC50 = 5.25 ×  10–6 ± 1.36 ×  10−6  M, max. developed tension (per-
cent) = 88.97 ± 8.28
Fig. 5  Effect of indomethacin and NO-indomethacin on the cumu-
lative log[concentration]—vasoconstrictor responses of fallow 
deer isolated arterial rings to 5-HT. A comparison of the contrac-
tile responses of arterial rings to 5-HT in the presence and absence 
of indomethacin  (10–4  M) and NO-indomethacin  (10–4  M,) showed 
that while indomethacin had no significant effect on the responses 
of the arterial rings to 5-HT (P > 0.05), NO-indomethacin, sig-
nificantly reduced the maximum tension produced (P < 0.001), 
but without significant effect on the  EC50 value when compared 
with responses of control rings and rings in the presence of indo-
methacin. Control: n = 19,  EC50 = 4.29 ×  10–7 ± 1.63 ×  10–8  M, 
max. developed tension (percent) = 100.9 ± 0.81. Vehi-
cle: n = 8,  EC50 = 3.53 ×  10–7 ± 2.61 ×  10–8  M, max. devel-
oped tension (percent) = 91.43 ± 1.40. Indomethacin: 
n = 8,  EC50 = 8.20 ×  10–7 ± 4.78 ×  10–8  M, max. developed 
tension (percent) = 107.6 ± 1.55. NO-Indomethacin: n = 9, 
 EC50 = 3.56 ×  10–7 ± 3.17 ×  10–8  M, max. developed tension (per-
cent) = 62.37 ± 1.81
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same way as R-(−)-ibuprofen. As S-( +)-ibuprofen is much 
less effective than the R(−)-isomer, the activation must be 
very specific. Due to the similarity between flurbiprofen and 
ibuprofen, it is no surprise that the former causes relaxation. 
There is also the possibility that other heme proteins are 
involved. It has been suggested that ODQ is non-selective 
and may inhibit enzymes other than sGC (Feelisch et al. 
1999). This implies that NO-generating enzymes could be 
activated by R-(−)-ibuprofen, the effect of which is then 
blocked by ODQ. However, most sources claim that ODQ 
is a specific sGC inhibitor. An assay directly testing the 
effect of R-(−)-ibuprofen and flurbiprofen on the activity of 
guanylate cyclase could verify this claim. In a clinical set-
ting, this discovery could prove useful if the concentrations 
required sufficiently to activate sGC are within a normal 
therapeutic range. If so, an ibuprofen preparation made up 
with a larger percentage of R-(−) could cause vasodilatation 
allowing clearance of the drug from the stomach, possibly 
preventing damage. After this, the drug would be converted 
to the active, COX inhibiting S-( +)-enantiomer, having 
already had the desired gastroprotective effect. A propor-
tion of S-( +)-ibuprofen would also be available for immedi-
ate anti-inflammatory effect without waiting for conversion 
to take place. However, topical formulations of R-(−)-
ibuprofen might have significant advantages compared with 
those of diclofenac, but without the excessive gastro-toxicity 
of the latter (Rainsford 2009, 2012).
Fig. 6  Effect of naproxen and NO-naproxen on the cumula-
tive log[concentration]—vasoconstrictor responses of fallow deer 
isolated arterial rings to 5-HT. A comparison of the contractile 
responses of arterial rings to 5-HT in the presence and absence 
of naproxen  (10–4  M) and NO-naproxen  (10–4  M), showed that 
naproxen had no significant effect on the responses of the arte-
rial rings to 5-HT, while NO- naproxen, significantly reduced 
the maximum tension produced (P < 0.05) together with a sig-
nificant increase in the  EC50 of applied 5-HT (P < 0.001), when 
compared with responses of control rings. However, there were 
no significant differences between NO-naproxen and naproxen 
(P > 0.05). Control: n = 19,  EC50 = 4.29 ×  10–7 ± 1.63 ×  10–8  M, 
max. developed tension (percent) = 100.9 ± 0.81. Vehi-
cle: n = 8,  EC50 = 3.53 ×  10–7 ± 2.61 ×  10–8  M, max. devel-
oped tension (percent) = 91.43 ± 1.40. Naproxen: n = 8, 
 EC50 = 6.66 ×  10–7 ± 5.99 ×  10–8  M, max. developed ten-
sion (percent) = 84.0 ± 1.68. NO-Naproxen: n = 12, 
 EC50 = 1.07 ×  10–6 ± 3.84 ×  10−8  M, max. developed tension (per-
cent) = 65.63 ± 0.56
Fig. 7  Effect of ibuprofen and NO-ibuprofen on the cumulative 
log[concentration]—vasoconstrictor responses of fallow deer isolated 
arterial rings to 5-HT. A comparison of the contractile responses 
of arterial rings to 5-HT in the presence and absence of ibupro-
fen and NO-ibuprofen show no significant difference between the 
effects of the two drugs on the rings’ responses to 5-HT (P > 0.05). 
At 5-HT concentrations of  10−6  M and  10−4  M the contraction in 
the presence of NO-ibuprofen is not significantly different from 
that of the control. Interestingly the results for classic ibuprofen 
show that the maximum contraction reached in the presence of this 
drug is less than that in the presence of NO-ibuprofen. Cumulative 
log[concentration]-response curve of the deer digital artery to 5-HT 
in the presence and absence of ibuprofen and ibuprofen nitroxy-
butyl ester. Control: n = 19,  EC50 = 4.29 ×  10–7 ± 1.63 ×  10–8  M, 
max. developed tension (percent) = 100.9 ± 0.81. Vehi-
cle: n = 8,  EC50 = 3.53 ×  10–7 ± 2.61 ×  10–8  M, max. devel-
oped tension (percent) = 91.43 ± 14.0. Ibuprofen: n = 7, 
 EC50 = 4 .04 ×  10–7 ± 4.19 ×  10−8  M, max. developed ten-
sion (percent) = 87 ± 0.21. (NO-Ibuprofen: n = 12, 
 EC50 = 7.02 ×  10–7 ± 1.78 ×  10−8  M, max. developed tension (per-
cent) = 81.9 ± 0.48
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Fig. 8  Effect of increasing concentrations of S-( +)-ibuprofen and 
R-(-)-ibuprofen on the tension produced in fallow deer isolated arte-
rial rings by a constant concentration of 3 ×  10–6 M 5-HT. S-( +)-ibu-
profen, in concentrations up to  10–4 M had no significant effect on the 
maintained tension (n = 4; P > 0.05), but R-(−)-ibuprofen had a sig-
nificant relaxant effect, first seen at 5 ×  10–7 M (n = 6; P < 0.05). (con-
trol tension: n = 6 and points of significance are shown as: *P < 0.05, 
**P < 0.01)
Fig. 9  Effect of increasing concentrations of S-( +)-flurbiprofen 
and R-(−)-flurbiprofen on the tension produced in fallow deer iso-
lated arterial rings by a constant concentration of 3 ×  10–6  M 5-HT. 
S-( +)-flurbiprofen, in concentrations up to  10–4  M had no signifi-
cant effect on the maintained tension (n = 6; P > 0.05), but R-(−)-
flurbiprofen had a significant relaxant effect, first seen at  10–6  M 
(n = 8; P < 0.05). (control tension: n = 6 and points of significance are 
shown as: *P < 0.05, **P < 0.01)
Fig. 10  Effect of increasing concentrations of R-(−)-ibuprofen on the 
tension produced in fallow deer isolated arterial rings by a constant 
concentration of 3 ×  10–6  M 5-HT, in the presence and absence of 
vascular endothelium. While there appears to be no significant differ-
ence (P > 0.05) between the maximum relaxation produced by R-(−)-
ibuprofen in the presence (n = 6) and absence (n = 5) of endothelium, 
at lower concentrations the difference is significant. At  10–7 M R-(−)-
ibuprofen the relaxation in the presence of endothelium is significant 
(*P < 0.05), while in its absence it is not; a difference even more 
marked at 3 ×  10–7 M. (control tension: n = 6, the asterisks denote lev-
els of significance between drug treated and control)
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